Okta: Oversold SaaS Stock Pinned on AI Agent Monetization

What happened

Okta's stock has been swept up in the broad SaaS selloff, but a recent Seeking Alpha article argues it is oversold given its unique position as the independent identity layer for securing AI agents. Management touts that contracts including new agentic solutions drive 40% value uplift, leveraging vendor neutrality across diverse cloud ecosystems. The master report from DeepValue confirms the narrative but maintains a WAIT rating, noting that AI-agent identity products only became generally available on April 30, 2026, and have yet to contribute measurable bookings. Core expansion is still fragile, with dollar-based net retention at 106% and cRPO growth in the low teens. The stock at $76 offers strong cash generation but requires visible inflection in forward indicators like cRPO and DBNRR to justify re-rating.

Implication

The article reinforces the bull case hinged on AI-agent governance becoming a growth catalyst, but the master report's discipline is warranted. Near-term, Okta's core revenue growth remains decelerating (9% guided for FY27) and the $350M note maturity in June 2026 is a liquidity event. The 40% contract uplift cited is anecdotal and not yet visible in reported metrics. Attractive entry remains near $65 (bear case) or after 1-2 quarters of improving DBNRR and cRPO. The market is likely to remain skeptical until Q1 FY27 results show early paid adoption of 'Okta for AI Agents.' Investor should not chase the narrative without observable booking data.

Thesis delta

The Seeking Alpha article presents a more bullish near-term outlook than the master report, emphasizing oversold conditions and early AI-agent traction. However, the master report's WAIT rating remains appropriate because the article's 40% uplift claim is unverified and the core business metrics (DBNRR 106%, cRPO +12%) have not inflected. The thesis shifts from cautious neutrality (wait for confirmation) to acknowledging that if AI-agent monetization materializes faster than expected, the stock could re-rate above $95. But without hard data, the risk/reward still favors waiting for measurable improvement in cRPO growth and DBNRR.